Empirical treatment of Shigella dysentery with trimethoprim: five-day course vs. single dose.
Fifty-three adults hospitalized with Shigella dysentery were empirically treated with trimethoprim (200 mg) twice/day for 5 days, a single dose of trimethoprim (600 mg), or placebo in a randomized double-blind trial. During the first 24 hr of therapy, there was a reduction in the number of stools in 18/21 (86%) of patients treated with the 5-day regimen (trimethoprim-5) and 13/15 (87%) of patients treated with a single dose (trimethoprim-1), compared with 7/17 (41%) of the placebo group (P less than 0.025, both comparisons). The mean number of stools passed in the first 24 hr of therapy was 10.6, 10.8, and 21.3 stools in the trimethoprim-5, trimethoprim-1, and placebo groups, respectively. The mean (+/- SD) change in number of stools from baseline among treated patients during the first 24 hr was -4.9 (6.6) and -6.3 (6.3) for the trimethoprim-5 and trimethoprim-1 groups, respectively, compared with an increase of +2.4 (14.8) for the placebo group. There was a clinical failure at 48 hr in 9% of the trimethoprim-5 patients and 13% of trimethoprim-1 patients compared with 70% of placebo patients (P less than 0.005, both comparisons). Although we were unable to demonstrate a difference in efficacy between the two dosage schedules of trimethoprim, we conclude that both treatment regimens are effective for the treatment of Shigella dysentery.
Oldfield
E C
EC
Department of Epidemiology, U.S. Naval Medical Research Unit No. 3, Cairo, Egypt.
Bourgeois
A L
AL
Omar
A K
AK
Pazzaglia
G L
GL
D000293:Adolescent; D000328:Adult; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004405:Dysentery, Bacillary / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D011897:Random Allocation; D012760:Shigella / Q000302:isolation & purification; D014295:Trimethoprim / Q000008:administration & dosage / Q000627:therapeutic use*
D014295:Trimethoprim